Vitrolife

Vitrolife EBITDA per Employee

The EBITDA per Employee of Vitrolife (VITR.ST) as of Nov 11, 2026 is 2.08 M SEK. In the previous year, EBITDA per Employee was 2.50 M SEK — a change of -17.00% (lower).

EBITDA per Employee

2.08 MSEK

YoY

-17.00%

Last updated:

EBITDA per Employee of Vitrolife is 2025 2.08 M SEK. EBITDA per Employee of Vitrolife was 2024 2.50 M SEK. It decreases by -17.00% lower compared to the previous year.

The Vitrolife EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
954,700.96 SEK
Jan 1, 2019
1.22 M SEK
Jan 1, 2020
936,232.06 SEK
Jan 1, 2021
1.16 M SEK
Jan 1, 2022
2.11 M SEK
Jan 1, 2023
-8.04 M SEK
Jan 1, 2024
2.50 M SEK
Jan 1, 2025
2.08 M SEK
The Vitrolife EBITDA per Employee history
YEAREBITDA per EmployeeYoY
2.08 MSEK-17.00%
2.50 MSEK-131.15%
-8.04 MSEK-481.93%
2.11 MSEK+82.23%
1.16 MSEK+23.40%
936,232.06SEK-23.25%
1.22 MSEK+27.77%
954,700.96SEK+14.94%
830,581.34SEK+35.16%
614,533.49SEK+13.59%
540,992.82SEK+57.75%
342,933.01SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vitrolife Stock analysis

What does Vitrolife do? Vitrolife AB is a Swedish biotech company specializing in the development and marketing of products for in vitro fertilization (IVF) and regenerative medicine. It was founded in 1994 and has over 390 employees worldwide. The company's main business is IVF, offering a wide range of essential products for IVF treatment such as culture media, devices for semen analysis and preparation, embryo transfer techniques, and products for biopsy examinations and cryopreservation. Vitrolife has a presence in 110 countries and has expanded its market to China where there is a high demand for fertility treatments. The company also offers medical equipment for regenerative treatments. Vitrolife is a leading player in the IVF industry known for its high product quality and innovation. It collaborates with universities and research institutions globally to improve IVF technology and success rates. The company places importance on sustainability and environmental protection, using 100% animal-free ingredients in their culture media and practicing recycling and waste reduction in their production facilities. In summary, Vitrolife offers a wide range of products for IVF and regenerative medicine, with a focus on supporting IVF treatments. The company is a leader in its industry and actively participates in research. It is committed to sustainability and environmental responsibility. Vitrolife is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vitrolife stock

EBITDA per Employee of Vitrolife is 2.08 M SEK in 2025.

EBITDA per Employee of Vitrolife changed from 2.50 M SEK to 2.08 M SEK, representing a -17.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Vitrolife since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Vitrolife historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Vitrolife

All Key Metrics — Vitrolife